Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Claudio Romano
 + 1764 word(s) 1764 2021-04-02 10:52:13 |
2 format correct
Catherine Yang
 Meta information modification 1764 2021-04-13 02:58:37 |

Video Upload Options

We provide professional Video Production Services to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Romano, C. Nutrition in Pediatric IBD. Encyclopedia. Available online: https://encyclopedia.pub/entry/8622 (accessed on 16 November 2024).
Romano C. Nutrition in Pediatric IBD. Encyclopedia. Available at: https://encyclopedia.pub/entry/8622. Accessed November 16, 2024.
Romano, Claudio. "Nutrition in Pediatric IBD" Encyclopedia, https://encyclopedia.pub/entry/8622 (accessed November 16, 2024).
Romano, C. (2021, April 12). Nutrition in Pediatric IBD. In Encyclopedia. https://encyclopedia.pub/entry/8622
Romano, Claudio. "Nutrition in Pediatric IBD." Encyclopedia. Web. 12 April, 2021.
Nutrition in Pediatric IBD
Edit
This entry is adapted from the peer-reviewed paper 10.3390/nu13020655

Inflammatory bowel disease (IBD) refers to a heterogeneous group of disorders encompassing Crohn’s disease (CD), ulcerative colitis (UC) and unclassified inflammatory bowel disease (IBD-U), characterized by a chronic inflammation of the intestinal tract with a relapsing-remitting behavior, and variably presenting with abdominal pain, diarrhea, rectal bleeding and weight loss. Dietary factors and malnutrition play a primary role in the onset and management of pediatric IBD. Moreover, an appropriate diet can decrease the risk of IBD flares, and an age-adequate nutritional status can decrease the risk of complications and surgery in the long-term stage of the disease. Enteral nutrition has a significant impact on mucosal inflammation in CD, and clinical response to oral polymeric diet is associated with down-regulation of mucosal pro-inflammatory cytokines. Nutritional strategies, such as exclusive enteral nutrition or CDED diet, have shown to be more effective than steroids in inducing clinical remission in pediatric patients.

enteral nutrition inflammatory bowel disease

1. Introduction

Inflammatory bowel disease (IBD), mainly represented by Crohn’s disease (CD) and ulcerative colitis (UC), are life-long and systemic disorders with a gut predominance, variably presenting with abdominal pain, diarrhea, rectal bleeding and weight loss. It is well known that IBD has a multifactorial etiology, but despite the ongoing scientific efforts, pathogenesis and pathophysiology are still unclear. The prevailing hypothesis accounts a complex interaction between an exaggerated immune response in genetically predisposed individuals and environmental factors along with intestinal flora alterations, eventually sustaining an anomalous chronic inflammation [1][2]. In the last decades, the incidence of IBD has significantly grown in industrialized countries, in children as in adults, and the increasing “westernization” of lifestyle seems to be associated with a higher risk of IBD. Indeed, several studies have been conducted in the past to evaluate the precise role of nutrition (and malnutrition) and diet composition in immune-mediated diseases risk, leading to the development of a new discipline, referred to as “clinical nutrition”. Clinical nutrition is defined by European Society for Clinical Nutrition and Metabolism (ESPEN) as the “discipline that deals with the prevention, diagnosis and management of nutritional and metabolic changes related to acute and chronic diseases and conditions caused by a lack or excess of energy and nutrients”[3]. It encompasses all the diseases in which nutrition plays a main role, not only as a promoter, but also as a therapeutic tool. For what IBD is concerned, the relation between diet composition and disease onset, course and management is supported by scientific evidence: i) epidemiological studies found an association between specific dietary habits and nutrients with an increased risk of IBD; ii) some foods and dietary components are potentially capable to either enhance or reduce the severity of inflammation; iii) for some pediatric patients with an established diagnosis of CD, exclusive enteral nutrition (EEN) can be considered a primary induction treatment with efficacy in achieving mucosal healing; iv) exclusion diets could treat or prevent disease flares; v) in IBD children, especially in CD children, malnutrition and nutrients deficiencies are often present at diagnosis; vi) early nutritional strategies can lead to a better disease control, as well as catch-up growth, bone mineral density improvement and adequate pubertal development[4][5][6]. The most common therapeutic choices for pediatric IBD consist of systemic and topical corticosteroids, amino salicylate and immunosuppressants (such as thiopurines or methotrexate). Starting from the past decade, use of biologic therapies has significantly increased for their clear efficacy also in pediatric setting. Beside this, non-pharmacological management of pediatric IBD has evolved over years and dietary changes are currently considered major therapeutic tools[6][7].

2. Nutrition and Diet and Intestinal Inflammation

The role of the diet composition in the intestinal inflammation has long been controversial, due to sometimes limited and conflicting data resulting from retrospective and case-control studies. The increasingly “westernization” of lifestyle, mostly characterized by a high consumption of animal proteins and fats along with a poor intake of fruit, vegetables and fibers is associated with a higher risk of IBD[8][9]. There is enough evidence to support that a low intake of omega-3 (n-3) and a high one of omega-6 (n-6) polyunsaturated fatty acids (PUFAs) is associated with an increased risk of CD. N-6 PUFAs (i.e., linoleic acid) are precursors to proinflammatory eicosanoids, whereas dietary n-3 PUFAs inhibits the formation of proinflammatory prostaglandins and leukotrienes through the arachidonic acid pathway, so their chronic imbalanced consumption may eventually lead to a pro- inflammatory state, oxidative stress and impaired intestinal mucosal permeability[10]. On the other side, a long-term intake of dietary fiber, particularly derived from fruit, has been associated with lower risk of CD, while no or conflicting association with UC has been found [11]. The most recent ESPEN guidelines recommend a diet rich in fruit and vegetables and low in n-6 PUFAs[12]. Western diet increases the risk of disease through food additives like emulsifiers and saturated fats, maltodextrins, carrageenin and carboxymethylcellulose, that have been associated with impaired intestinal permeability[13][14][15][16].

Even early life dietary patterns can be considered risk factors. Breast milk is rich in secretory IgA (sIgA), leukocytes and antimicrobial factors (lysozyme, lactoferrin, nucleotides), and promotes immune system maturation and T-lymphocytes pool creation, as well as immune response against infections[17]. It has been suggested that an early discontinuation of breastfeeding may facilitate the onset of several chronic conditions later in life, such as metabolic and autoimmune diseases. A recent meta-analysis comparing the exposure to breast milk among patients with CD and UC and controls confirmed an inverse association between breastfeeding and the risk of developing IBD[18]. Moreover, a dose depending effect has been hypothesized, with higher protection for longer-lasting breast milk exposure[18]. Additionally, since microbiome has been proven to differ according to the type of early diet, with relatively higher proportion of Firmicutes and Actinobacteria in breast-fed infants, it seems reasonable to assume that dysbiosis during the first months of life may negatively impact on immunological functions of the host microbiota[19][20][21].

Indeed, IBD has been consistently associated with gut dysbiosis, variably determined by specific foods and dietary habits. While commensal microbiome is physiologically abundant in Firmicutes, Bacteroidetes, Actinobacteria and Proteobacteria, IBD patients typically exhibit a low concentration of Firmicutes, such as Bifidobacterium, Clostridia and especially Faecalibacterium prausnitzii, whose protective role has been theorized for the possibility to stimulate anti-inflammatory cytokines (including IL-10). Conversely, increased concentrations of Escherichia Coli and other Enterobacteriacee has been found[22][23]. Even metabolic pathways are altered, because short chain fatty acids (SCFAs), such as acetate, propionate, and butyrate, normally produced by commensal bacteria through fermentation of food components, have been found reduced in IBD compared to controls. Further evidence includes reduced tryptophan metabolism and disrupted bile acids metabolism, with low bile acids production, classically associated with anti-inflammatory activities and T-cells regulation. All these alterations eventually contribute to a decreased bacterial diversity, altered host barrier, increased permeability and subsequent intestinal inflammation.

3. Nutritional strategies in the treatment of Inflammatory Bowel Diseases

It is recognized that dietary factors and malnutrition play a primary role in the onset and management of pediatric IBD. An appropriate diet can decrease the risk of IBD flares, and an age-adequate nutritional status can decrease the risk of complications and surgery in the long-term stage of the disease. Enteral nutrition has a significant impact on mucosal inflammation in CD, and clinical response to oral polymeric diet is associated with down-regulation of mucosal pro-inflammatory cytokines.

Exclusive enteral nutrition (EEN) is the most important nutritional intervention in pediatric IBD, consisting of a complete liquid formula as the unique source of daily energy requirement for a period of 6-8 weeks. Consensus guidelines of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and European Crohn’s Colitis Organization (ECCO), as well as North American guidelines, recommend EEN as the first-line therapy for mild to moderate pediatric CD to induce remission both in the first flare-up and during relapses of symptoms[24][25][26]. The main indication for EEN is represented by active luminal CD, with solely inflammatory behavior (B1 according to Paris classification) and low-to-medium risk at diagnosis, regardless of the disease location[25]. EEN advantages include: (i) high rates (up to 80%) of clinical remission; (ii) steroids sparing; (iii) correction of malnutrition and micronutrients deficiency; (iv) lean body mass increase; (v) improvement of growth and height Z scores; (vi) decreased longer term need for steroid and anti-TNF therapies; (vii) improvement of quality of life (QoL). EEN is delivered through the administration of enteral nutrition (EN) formulas, avail- able in a wide range of commercial formulations. A nutritionally balanced polymeric formula should be the preferred choice in patients with intestinal sufficiency and in the absence of other medical conditions (e.g., co-existence of a cow’s milk allergy).

Further nutritional strategy is represented by the Crohn’s Disease Exclusion Diet (CDED), a validated dietary intervention firstly conceived in 2014 by Sigall-Boneh and colleagues, combining PEN with a specific exclusion diet.[27] The rationale of CDED is the avoidance of certain foods and dietary components (such as additives like emulsifiers or maltodextrins, food preservatives, etc), mostly belonging to western diets, deemed to act as triggers for intestinal inflammation, dysbiosis, altered intestinal mucous layer and impaired barrier function. CDED owes its progressive diffusion both to the high efficacy in terms of clinical remission and to its variability, leading to a better acceptance by patients.[28] The foods are classified into three main groups: mandatory foods, allowed foods and not allowed foods. CDED is then designed in 3 phases: the first two induction phases lasting 6 weeks each, while the third one starting from the 13th week and referred to as “maintenance phase”. During the first phase, 50% of nutritional requirement is given in the form of a polymeric formula, poor in lactose and fibers (e.g., Modulen, Nestlè), while the remaining 50% is supplied by mandatory foods, source of high-quality proteins, pectin, resistant starch and other beneficial fibers, all necessary for the production of SCFAs. During the second phase the percentage of calories provided by the liquid formula is lowered to 25%, more foods are permitted with higher inclusion of fruits and vegetables and little quantities of bread, red meat and legumes (found to potentially aggravate symptoms). The third and last phase still consists of 25% polymeric formula and does not have a specific duration, allowing the patient to continue with a controlled diet, rich in healthy foods, with the final aim of better controlling the disease in the long term. [27][28]

Further exclusion diets have been proposed, including  the Crohn’s Disease Treatment With Eating Diet (CD-TREAT), the Specific Carbohydrate Diet (SCD), the Diet Low in Fermentable Oligo-, Di- and Monosaccharides and Polyol (FODMAPs), the Paleolithic Diet, and the Vegan Diet. Although some of them have shown interestingly results, further studies are necessary in order to establish their real efficacy. [29][30][31]

References

  1. Ing Shian Soon; Natalie A Molodecky; Doreen M Rabi; William A Ghali; Herman W Barkema; Gilaad G Kaplan; The relationship between urban environment and the inflammatory bowel diseases: a systematic review and meta-analysis. BMC Gastroenterology 2012, 12, 51-51, 10.1186/1471-230x-12-51.
  2. Alfredo José Lucendo; Livia Cristina De Rezende; Importance of nutrition in inflammatory bowel disease. World Journal of Gastroenterology 2009, 15, 2081-2088, 10.3748/wjg.15.2081.
  3. T. Cederholm; R. Barazzoni; P. Austin; P. Ballmer; G. Biolo; S.C. Bischoff; C. Compher; I. Correia; T. Higashiguchi; M. Holst; et al.G.L. JensenA. MaloneM. MuscaritoliI. NyulasiM. PirlichE. RothenbergK. SchindlerS.M. SchneiderM.A.E. De Van Der SchuerenC. SieberL. ValentiniJ.C. YuA. Van GossumP. Singer ESPEN guidelines on definitions and terminology of clinical nutrition. Clinical Nutrition 2017, 36, 49-64, 10.1016/j.clnu.2016.09.004.
  4. Jason K Hou; Bincy Abraham; Hashem El-Serag; Dietary Intake and Risk of Developing Inflammatory Bowel Disease: A Systematic Review of the Literature. American Journal of Gastroenterology 2011, 106, 563-573, 10.1038/ajg.2011.44.
  5. Philipp Schreiner; Maude Martinho-Grueber; Diana Studerus; Stephan R. Vavricka; Herbert Tilg; Luc Biedermann; Nutrition in Inflammatory Bowel Disease. Digestion 2020, 101, 120-135, 10.1159/000505368.
  6. Alastair Forbes; Johanna Escher; Xavier Hébuterne; Stanisław Kłęk; Zeljko Krznaric; Stéphane Schneider; Raanan Shamir; Kalina Stardelova; Nicolette Wierdsma; Anthony E. Wiskin; et al.Stephan C. Bischoff ESPEN guideline: Clinical nutrition in inflammatory bowel disease. Clinical Nutrition 2017, 36, 321-347, 10.1016/j.clnu.2016.12.027.
  7. Hamed Khalili; Simon S. M. Chan; Paul Lochhead; Ashwin N. Ananthakrishnan; Andrew R. Hart; Andrew T. Chan; The role of diet in the aetiopathogenesis of inflammatory bowel disease. Nature Reviews Gastroenterology & Hepatology 2018, 15, 525-535, 10.1038/s41575-018-0022-9.
  8. Tanya Yatsunenko; Federico E. Rey; Mark J. Manary; Indi Trehan; Maria Gloria Dominguez-Bello; Monica Contreras; Magda Magris; Glida Hidalgo; Robert N. Baldassano; Andrey P. Anokhin; et al.Andrew C. HeathBarbara B WarnerJens ReederJustin KuczynskiJ. Gregory CaporasoCatherine A. LozuponeChristian L LauberJose Carlos ClementeDan KnightsRob KnightJeffrey I. Gordon Human gut microbiome viewed across age and geography. Nature 2012, 486, 222-227, 10.1038/nature11053.
  9. Vibeke H. Telle-Hansen; Kirsten B. Holven; Stine M. Ulven; Impact of a Healthy Dietary Pattern on Gut Microbiota and Systemic Inflammation in Humans. Nutrients 2018, 10, 1783, 10.3390/nu10111783.
  10. Ashwin N. Ananthakrishnan; Hamed Khalili; Gauree G. Konijeti; Leslie M. Higuchi; Punyanganie De Silva; Charles S. Fuchs; Walter C. Willett; James M. Richter; Andrew T. Chan; Long-term intake of dietary fat and risk of ulcerative colitis and Crohn's disease. Gut 2013, 63, 776-784, 10.1136/gutjnl-2013-305304.
  11. Ashwin N. Ananthakrishnan; Hamed Khalili; Gauree G. Konijeti; Leslie M. Higuchi; Punyanganie de Silva; Joshua R. Korzenik; Charles S. Fuchs; Walter C. Willett; James M. Richter; Andrew T. Chan; et al. A Prospective Study of Long-term Intake of Dietary Fiber and Risk of Crohn's Disease and Ulcerative Colitis. Gastroenterology 2013, 145, 970-977, 10.1053/j.gastro.2013.07.050.
  12. Stephan C. Bischoff; Johanna Escher; Xavier Hébuterne; Stanisław Kłęk; Zeljko Krznaric; Stéphane Schneider; Raanan Shamir; Kalina Stardelova; Nicolette Wierdsma; Anthony E. Wiskin; et al.Alastair Forbes ESPEN practical guideline: Clinical Nutrition in inflammatory bowel disease. Clinical Nutrition 2020, 39, 632-653, 10.1016/j.clnu.2019.11.002.
  13. Kourtney P. Nickerson; Christine McDonald; Crohn's Disease-Associated Adherent-Invasive Escherichia coli Adhesion Is Enhanced by Exposure to the Ubiquitous Dietary Polysaccharide Maltodextrin. PLOS ONE 2012, 7, e52132, 10.1371/journal.pone.0052132.
  14. Carol L. Roberts; Sarah L. Rushworth; Emile Richman; Jonathan M. Rhodes; Hypothesis: Increased consumption of emulsifiers as an explanation for the rising incidence of Crohn's disease. Journal of Crohn's and Colitis 2013, 7, 338-341, 10.1016/j.crohns.2013.01.004.
  15. John Vincent Martino; Johan Van Limbergen; Leah E. Cahill; The Role of Carrageenan and Carboxymethylcellulose in the Development of Intestinal Inflammation. Frontiers in Pediatrics 2017, 5, 96, 10.3389/fped.2017.00096.
  16. Rotem Sigall-Boneh; Arie Levine; Miranda Lomer; Nicolette Wierdsma; Philip Allan; Gionata Fiorino; Simona Gatti; Daisy Jonkers; Jarosław Kierkuś; Konstantinos H Katsanos; et al.Silvia MelgarElif Saritas YukselKevin WhelanEytan WineKonstantinos Gerasimidis Research Gaps in Diet and Nutrition in Inflammatory Bowel Disease. A Topical Review by D-ECCO Working Group [Dietitians of ECCO]. Journal of Crohn's and Colitis 2017, 11, 1407-1419, 10.1093/ecco-jcc/jjx109.
  17. Sara M. Parigi; Maria Eldh; Pia Larssen; Susanne Gabrielsson; Eduardo J. Villablanca; Breast Milk and Solid Food Shaping Intestinal Immunity. Frontiers in Immunology 2015, 6, 415, 10.3389/fimmu.2015.00415.
  18. Luyi Xu; Paul Lochhead; Yanna Ko; Brian Claggett; Rupert W Leong; Ashwin N Ananthakrishnan; Systematic review with meta-analysis: breastfeeding and the risk of Crohn's disease and ulcerative colitis. Alimentary Pharmacology & Therapeutics 2017, 46, 780-789, 10.1111/apt.14291.
  19. Cian J. Hill; Denise B. Lynch; Kiera Murphy; Marynka Ulaszewska; Ian B. Jeffery; Carol Anne O’Shea; Claire Watkins; Eugene Dempsey; Fulvio Mattivi; Kieran Tuohy; et al.R. Paul RossC. Anthony RyanPaul W. O’ TooleCatherine Stanton Evolution of gut microbiota composition from birth to 24 weeks in the INFANTMET Cohort. Microbiome 2017, 5, 1-18, 10.1186/s40168-016-0213-y.
  20. Daria A. Kashtanova; Anna S. Popenko; Olga N. Tkacheva; Alexander B. Tyakht; Dimitry G. Alexeev; Sergey A. Boytsov; Association between the gut microbiota and diet: Fetal life, early childhood, and further life. Nutrition 2016, 32, 620-627, 10.1016/j.nut.2015.12.037.
  21. Juliette C. Madan; Anne Gatewood Hoen; Sara N. Lundgren; Shohreh F. Farzan; Kathryn L. Cottingham; Hilary G. Morrison; Mitchell L. Sogin; Hongzhe Li; Jason H. Moore; Margaret R. Karagas; et al. Association of Cesarean Delivery and Formula Supplementation With the Intestinal Microbiome of 6-Week-Old Infants. JAMA Pediatrics 2016, 170, 212-219, 10.1001/jamapediatrics.2015.3732.
  22. Rapat Pittayanon; Jennifer T. Lau; Grigorios I. Leontiadis; Frances Tse; Yuhong Yuan; Michael Surette; Paul Moayyedi; Differences in Gut Microbiota in Patients With vs Without Inflammatory Bowel Diseases: A Systematic Review. Gastroenterology 2020, 158, 930-946.e1, 10.1053/j.gastro.2019.11.294.
  23. Arie Levine; Jonathan M. Rhodes; James O. Lindsay; Maria T. Abreu; Michael A. Kamm; Peter R. Gibson; Christoph Gasche; Mark S. Silverberg; Uma Mahadevan; Rotem Sigall Boneh; et al.Eyton WineOriana M. DamasGraeme SymeGina L. TrakmanChu Kion YaoStefanie StockhamerMuhammad B. HammamiLuis C. GarcesGerhard RoglerIoannis E. KoutroubakisAshwin N. AnanthakrishnanLiam McKeeverJames D. Lewis Dietary Guidance From the International Organization for the Study of Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology 2020, 18, 1381-1392, 10.1016/j.cgh.2020.01.046.
  24. F.M. Ruemmele; G. Veres; K.L. Kolho; A. Griffiths; A. Levine; J.C. Escher; J. Amil Dias; A. Barabino; C.P. Braegger; J. Bronsky; et al.S. BuderusJ. Martín-De-CarpiL. De RidderU.L. FagerbergJ.P. HugotJ. KierkusS. KolacekS. KoletzkoP. LionettiE. MieleV.M. Navas LópezA. PaerregaardR.K. RussellD.E. SerbanR. ShaoulP. Van RheenenG. VeeremanB. WeissD. WilsonA. DignassA. EliakimH. WinterD. Turner Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. Journal of Crohn's and Colitis 2014, 8, 1179-1207, 10.1016/j.crohns.2014.04.005.
  25. Patrick F Van Rheenen; Marina Aloi; Amit Assa; Jiri Bronsky; Johanna C Escher; Ulrika L Fagerberg; Marco Gasparetto; Konstantinos Gerasimidis; Anne Griffiths; Paul Henderson; et al.Sibylle KoletzkoKaija-Leena KolhoArie LevineJohan Van LimbergenFrancisco Javier Martin De CarpiVíctor Manuel Navas-LópezSalvatore OlivaLissy De RidderRichard K RussellDror ShouvalAntonino SpinelliDan TurnerDavid WilsonEytan WineFrank M Ruemmele The Medical Management of Paediatric Crohn’s Disease: an ECCO-ESPGHAN Guideline Update. Journal of Crohn's and Colitis 2020, 15, 171-194, 10.1093/ecco-jcc/jjaa161.
  26. Erasmo Miele; Raanan Shamir; Marina Aloi; Amit Assa; Christian Braegger; Jiri Bronsky; Lissy de Ridder; Johanna C. Escher; Iva Hojsak; Sanja Kolaček; et al.Sibylle KoletzkoArie LevinePaolo LionettiMassimo MartinelliFrank RuemmeleRichard K. RussellRotem Sigall BonehJohan van LimbergenGigi VeeremanAnnamaria Staiano Nutrition in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto Inflammatory Bowel Disease Group of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. Journal of Pediatric Gastroenterology & Nutrition 2018, 66, 687-708, 10.1097/mpg.0000000000001896.
  27. Rotem Sigall-Boneh; Tamar Pfeffer-Gik; Idit Segal; Tsili Zangen; Mona Boaz; Arie Levine; Partial Enteral Nutrition with a Crohnʼs Disease Exclusion Diet Is Effective for Induction of Remission in Children and Young Adults with Crohnʼs Disease. Inflammatory Bowel Diseases 2014, 20, 1353-1360, 10.1097/mib.0000000000000110.
  28. Marta Herrador-López; Rafael Martín-Masot; Víctor Manuel Navas-López; EEN Yesterday and Today … CDED Today and Tomorrow. Nutrients 2020, 12, 3793, 10.3390/nu12123793.
  29. Vaios Svolos; Richard Hansen; Ben Nichols; Christopher Quince; Umer Z. Ijaz; Rodanthi T. Papadopoulou; Christine A. Edwards; David Watson; Adel Alghamdi; Asker Brejnrod; et al.Cecilia AnsaloneHazel DuncanLisa GervaisRachel TaylerJonathan SalmondDaniele BologniniRobert KlopfleischDaniel R. GayaSimon MillingRichard K. RussellKonstantinos Gerasimidis Treatment of Active Crohn’s Disease With an Ordinary Food-based Diet That Replicates Exclusive Enteral Nutrition. Gastroenterology 2019, 156, 1354-1367.e6, 10.1053/j.gastro.2018.12.002.
  30. Salvatore Oliva; Benjamin D. Gold; Jeffrey Lewis; Angela Stallworth; Bailey Koch; Laura Eshee; Salvatore Cucchiara; Stanley A. Cohen; Clinical and mucosal improvement with specific carbohydrate diet in pediatric Crohn disease. Digestive and Liver Disease 2014, 46, e83-e84, 10.1016/j.dld.2014.07.051.
  31. Richard B. Gearry; Peter M. Irving; Jacqueline S. Barrett; Debbie M. Nathan; Sue J. Shepherd; Peter R. Gibson; Reduction of dietary poorly absorbed short-chain carbohydrates (FODMAPs) improves abdominal symptoms in patients with inflammatory bowel disease—a pilot study. Journal of Crohn's and Colitis 2009, 3, 8-14, 10.1016/j.crohns.2008.09.004.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Gastroenterology & Hepatology
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Claudio Romano
View Times: 543
Revisions: 2 times (View History)
Update Date: 13 Apr 2021
Table of Contents
    1000/1000
    Hot Most Recent
    ScholarVision Creations
    Feedback